第十一批药品集采竞争格局显现，国家医保局提示投标企业理性报价

Core Viewpoint - The National Healthcare Security Administration (NHSA) is optimizing drug procurement measures in accordance with the State Council's directives, focusing on maintaining clinical stability, ensuring quality, preventing collusion, and avoiding excessive competition [1] Group 1: Drug Procurement Measures - The NHSA, in collaboration with relevant departments, is advancing the 11th batch of national drug procurement, with 55 drugs identified for inclusion in the procurement scope [1] - From July 16 to 31, the Drug Procurement Office organized information collection for the relevant drugs, with 480 companies submitting their data [1] - On average, each of the 55 drugs has 15 participating companies, with three drugs having over 40 companies, and the highest number of companies for a single drug reaching 45 [1] Group 2: Participation and Compliance - The NHSA encourages qualified companies to actively participate in this procurement process to provide high-quality and affordable drugs to the public [1] - Companies are advised to conduct cost-benefit analyses, assess market competition rationally, and maintain integrity in pricing to combat illegal practices such as collusion [1] - The Drug Procurement Office will draft and publish procurement documents and further verify the qualifications and relationships of the bidding companies [1]